| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
RLAY
Relay Therapeutics
|
Jun 18, 2026 | BUY |
Strong Buy
+26.3% avg upside
19 analysts
|
— | +0.0% |
|
DNTH
Dianthus Therapeutics
|
Jun 12, 2026 | BUY |
Strong Buy
+8.8% avg upside
29 analysts
|
— | +0.5% |
|
IONS
Ionis Pharmaceuticals
|
Jun 12, 2026 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$108.00
45.79% Upside
|
+0.0% |
|
ONC
BeOne Medicines
|
Jun 02, 2026 | BUY |
Strong Buy
+28.4% avg upside
28 analysts
|
$424.00
56.91% Upside
|
-1.7% |
|
NUVB
Nuvation Bio
|
Jun 01, 2026 | BUY |
Strong Buy
+132.2% avg upside
15 analysts
|
— | +7.5% |
|
KLRA
Kailera Therapeutics, Inc.
|
May 26, 2026 | BUY |
Strong Buy
+96.0% avg upside
5 analysts
|
— | · |
|
AMGN
Amgen
|
May 18, 2026 | BUY |
Buy
-11.6% avg upside
57 analysts
|
$326.31
3.44% Downside
|
+4.1% |
|
ROIV
Roivant Sciences
|
May 18, 2026 | BUY |
Strong Buy
+2.5% avg upside
17 analysts
|
$29.29
6.84% Downside
|
+8.2% |
|
ARGX
Argenx Se
|
May 18, 2026 | BUY |
Strong Buy
-15.8% avg upside
46 analysts
|
$799.32
8.97% Downside
|
+13.7% |
|
JSPR
Jasper Therapeutics
|
May 15, 2026 | HOLD |
Strong Buy
+6361.2% avg upside
17 analysts
|
— | -44.6% |
|
LEGN
Legend Biotech
|
May 13, 2026 | HOLD |
Strong Buy
+140.3% avg upside
27 analysts
|
$29.00
3.79% Upside
|
+25.1% |
|
UPB
Upstream Bio, Inc.
|
May 13, 2026 | BUY |
Strong Buy
+514.9% avg upside
9 analysts
|
— | -31.1% |
|
VOR
Vor Biopharma
|
May 13, 2026 | BUY |
Buy
+199.3% avg upside
17 analysts
|
— | -8.9% |
|
PMVP
PMV Pharmaceuticals
|
May 12, 2026 | BUY |
Strong Buy
+1200.9% avg upside
12 analysts
|
— | -9.2% |
|
FBRX
Forte Biosciences
|
May 11, 2026 | BUY |
Strong Buy
+128.0% avg upside
14 analysts
|
— | -11.1% |
|
SEPN
Septerna, Inc.
|
May 11, 2026 | BUY |
Strong Buy
+18.2% avg upside
12 analysts
|
— | +29.1% |
|
ZYME
Zymeworks
|
May 08, 2026 | BUY |
Strong Buy
+40.3% avg upside
25 analysts
|
— | -3.1% |
|
ASND
Ascendis Pharma
|
May 07, 2026 | BUY |
Strong Buy
+16.9% avg upside
24 analysts
|
$325.00
40.75% Upside
|
-6.1% |
|
FHTX
Foghorn Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+187.4% avg upside
17 analysts
|
— | +1.9% |
|
STOK
Stoke Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+25.1% avg upside
18 analysts
|
— | -8.5% |
|
ALEC
Alector
|
May 07, 2026 | HOLD |
Buy
+532.1% avg upside
14 analysts
|
— | -11.5% |
|
GMAB
Genmab
|
May 07, 2026 | HOLD |
Strong Buy
+38.3% avg upside
26 analysts
|
$32.00
26.64% Upside
|
-1.9% |
|
CLDX
Celldex
|
May 07, 2026 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
— | -2.7% |
|
EXEL
Exelixis
|
May 05, 2026 | BUY |
Strong Buy
-21.0% avg upside
33 analysts
|
$55.00
5.96% Upside
|
+19.6% |
|
RARE
Ultragenyx Pharmaceutical
|
May 05, 2026 | BUY |
Strong Buy
+142.1% avg upside
36 analysts
|
$49.00
78.55% Upside
|
-7.6% |
|
BNTX
BioNTech SE
|
May 05, 2026 | HOLD |
Strong Buy
+50.5% avg upside
26 analysts
|
$94.00
3.42% Upside
|
-4.8% |
|
PASG
Passage Bio
|
Apr 21, 2026 | HOLD |
Buy
+214.0% avg upside
14 analysts
|
— | -17.2% |
|
IOBTQ
IO Biotech
|
Mar 31, 2026 | HOLD |
Buy
+78483.3% avg upside
6 analysts
|
— | · |
|
NKTX
Nkarta
|
Mar 26, 2026 | BUY |
Strong Buy
+552.7% avg upside
15 analysts
|
— | +23.4% |
|
PANW
Palo Alto Networks
|
May 21, 2025 | BUY |
Strong Buy
-7.0% avg upside
73 analysts
|
$230.00
20.14% Downside
|
+39.5% |
|
GB:0QW0
arGEN X
|
Feb 21, 2025 | BUY |
Strong Buy
-22.9% avg upside
24 analysts
|
$664.00
13.75% Downside
|
· |
|
GB:0MGB
Genmab A/S
|
Apr 03, 2024 | HOLD |
Strong Buy
+31.6% avg upside
22 analysts
|
— | · |
|
IMRX
Immuneering
|
Mar 14, 2024 | HOLD |
Strong Buy
+303.9% avg upside
10 analysts
|
— | -44.8% |
|
DE:LEG
LEG Immobilien
|
Mar 11, 2024 | BUY |
Strong Buy
+65.3% avg upside
14 analysts
|
— | · |
|
KYNB
Kyntra Bio
|
Jun 26, 2023 | HOLD |
Buy
+370.8% avg upside
14 analysts
|
$3.00
55.30% Downside
|
-61.1% |
|
TIL
Instil Bio
|
Nov 01, 2022 | HOLD |
Buy
+343.3% avg upside
8 analysts
|
— | -86.1% |
|
REGN
Regeneron
|
Feb 08, 2021 | HOLD |
Strong Buy
+26.9% avg upside
57 analysts
|
$565.00
7.27% Downside
|
+24.9% |
|
OLMA
Olema Pharmaceuticals
|
Dec 14, 2020 | BUY |
Strong Buy
+303.4% avg upside
16 analysts
|
— | -77.5% |
|
RCKT
Rocket Pharmaceuticals
|
Aug 05, 2020 | BUY |
Buy
+391.0% avg upside
29 analysts
|
— | +41.7% |
|
LRMR
Larimar Therapeutics
|
Feb 21, 2020 | HOLD |
Strong Buy
+406.3% avg upside
21 analysts
|
— | +24.7% |
|
WVE
Wave Life Sciences
|
Dec 31, 2019 | HOLD |
Strong Buy
+260.5% avg upside
28 analysts
|
— | -1.9% |
|
COGT
Cogent Biosciences
|
Aug 12, 2019 | HOLD |
Strong Buy
+7.1% avg upside
26 analysts
|
— | +30.7% |
|
GILD
Gilead Sciences
|
Feb 25, 2016 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$110.00
11.08% Downside
|
-20.6% |
|
BIIB
Biogen
|
Feb 25, 2016 | BUY |
Buy
+25.1% avg upside
51 analysts
|
$345.00
75.51% Upside
|
+8.7% |
|
PBYI
Puma Biotechnology
|
Sep 03, 2015 | BUY |
Buy
+458.2% avg upside
11 analysts
|
$94.00
1143.37% Upside
|
-36.5% |
|
AGIO
Agios Pharma
|
Feb 18, 2015 | HOLD |
Strong Buy
+73.2% avg upside
29 analysts
|
$132.00
286.32% Upside
|
-66.2% |
|
ATRA
Atara Biotherapeutics
|
Nov 10, 2014 | BUY |
Buy
+79.6% avg upside
18 analysts
|
$37.00
267.41% Upside
|
+25.4% |
|
SRPT
Sarepta Therapeutics
|
Apr 22, 2014 | HOLD |
Buy
+244.5% avg upside
49 analysts
|
— | -65.1% |
|
RIGL
Rigel
|
Jun 04, 2013 | HOLD |
Strong Buy
-27.5% avg upside
17 analysts
|
$5.00
84.87% Downside
|
-12.9% |
|
VRTX
Vertex Pharmaceuticals
|
Apr 19, 2013 | BUY |
Strong Buy
-2.6% avg upside
61 analysts
|
$100.00
77.92% Downside
|
-25.0% |
|
ANTH
Anthera Pharmaceuticals
|
Mar 12, 2012 | HOLD |
Buy
+472857042.9% avg upside
9 analysts
|
$3.00
299999899.94% Upside
|
· |
|
GSK
GlaxoSmithKline
|
Nov 17, 2010 | HOLD |
Hold
-14.0% avg upside
19 analysts
|
— | +15.8% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.